Multi Institutional Retrospective Study about Median Survival Outcome for Women with Metastatic Triple Negative and HER2 Positive Breast Cancer in Egypt

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Hesham Ahmed El Gazaly ◽  
Ass. Prof. Dr. Amr Shafik Tawfik ◽  
Essam Saleh ◽  
Doaa Mohammed Abd ElHameed
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Targeted Therapy ◽  
Cancer Patients ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Survival Outcome ◽  
Breast Cancer Patients ◽  
University Hospitals

Abstract Background Breast cancer is the most common malignant tumor among females around the world. It represents 1.7 million new cases per year and 25% of all types of cancers. Objectives Assessment of median overall survival in most aggressive subtypes of metastatic breast cancer (Triple –Ve and HER2+Ve) & to compare survival of metastatic HER2+Ve breast cancer in group received targeted versus that did not receive. Patient and Methods Multi institutional retrospective study for assessment of median OS in metastatic breast cancer for themost aggressive subtypes (HER2+Ve &Triple-Ve) at Ain Shams University Hospitals and El-Matarya teaching Hospital. Results Seventy-three metastatic breast cancer patients were included (31 Triple-Ve & 42 HER2+Ve) in the period between January 2014 and December 2016 At Ain Shams University Hospitals and El-Matarya teaching Hospital, we found that median OS for Triple negative group is 16 months with (95% CI 8.8- 23.6) , that for HER2+Ve group is 17 months with (95% CI 13.9 – 20.6) & for patients did not receive targeted therapy, median OS is 10 months (95% CI. 4-19.4,P.000). Conclusion From our study,we highlight that metastatic breast cancer patients (HER2+Ve subtype) &received targeted therapy, had the most superior survival outcome. so,targeted therapy must be included in first line treatment.

scholarly journals Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

2021 ◽  
Vol 18 (10) ◽  
pp. 2245-2250
Author(s):  
Eriseld Krasniqi ◽  
Laura Pizzuti ◽  
Maria Rosaria Valerio ◽  
Elisabetta Capomolla ◽  
Claudio Botti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Second Line ◽  
Breast Cancer Patients ◽  
Multicentre Retrospective Study

Retrospective study comparing tolerability of weekly paclitaxel in two group of metastatic breast cancer patients: Age 65 and older compared with younger than age 65.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e20528-e20528
Author(s):  
Agnieszka I. Jagiello Gruszfeld ◽  
Zbigniew Nowecki ◽  
Izabela Lemanska ◽  
Renata Irena Sienkiewicz ◽  
Halina Rudnicka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Weekly Paclitaxel ◽  
Breast Cancer Patients

Efficacy and safety of metronomic capecitabine and gefitinib in heavily pretreated metastatic triple-negative breast cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1071-1071
Author(s):  
Anantbhushan Ranade ◽  
Kanaka Govind Babu ◽  
Purvish M. Parikh ◽  
Jk Singh ◽  
Manisha Singh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Visceral Metastasis ◽  
Egfr Expression ◽  
Heavily Pretreated

1071 Background: Metronomic chemotherapy regimens have shown efficacy in patients with metastatic breast cancer by antiangiogenic mechanisms. When used metronomically the toxicity profile of capecitabine is low. Triple negative breast cancer is a common problem in India and developing countries. Approximately 30% of triple negative breast cancer express EGFR and its mutation. Methods: Since October 2003 to December 2011 we objectively tested response rates, clinical benefit, and safety of gefitinib and capecitabine administered with a metronomic schedule of 500 mg thrice daily in heavily pretreated metastatic breast cancer patients with gefitinib 250 mg once daily. 300 patients were screened for EGFR expression. Among 85 enrolled patients with EGFR positivity, 76 were evaluable. ECOG performance status (PS) was 0-2, median age 52 years (range 36-65), bone plus visceral metastasis in 40% of patients. Rest had only visceral metastasis. All the patients were pretreated with anthracyclines and taxanes. The combination was administered for a median duration of 32 weeks (range 12-166). Results: We observed 18 partial responses (PR: 24%), 42 (55%) stable disease (SD). Median time to progression was 53 weeks, (95% CI, range 12-166 weeks). Safety of metronomic capecitabine with gefitinib was excellent. Neither grade 2-4 haematological or clinical side effects were recorded. Only 12 patients experienced grade I (WHO) hand-foot syndrome. Conclusions: Treatment with metronomic capecitabine and gefitinib was effective and minimally toxic in heavily pretreated breast cancer patients.

scholarly journals Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia.

2020 ◽  
Vol 1 (1) ◽  
pp. 9-14
Author(s):  
Shereef Elsamany ◽  
Omaima Elemam ◽  
Ahmed Zeeneldin ◽  
Soha Elmorsy ◽  
Ahmed Khatry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Saudi Arabia ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Metastatic Breast ◽  
Survival Outcome ◽  
Clinicopathological Factors ◽  
Breast Cancer Patients

Background Deficiency of vitamin-D (Vit-D) was associated with poor survival outcome in several studies across different tumour types. The present study aims to assess the prevalence and prognostic value of Vit-D deficiency among breast cancer patients in a single institution in Saudi Arabia. Methods In this retrospective study, we screened patients who presented with non-metastatic breast cancer to King Abdullah Medical City, Saudi Arabia from June 2011 to December 2015. We checked baseline Vit-D level before starting systemic therapy in addition to other clinicopathological factors. Low Vit-D was defined as Vit-D level less than 30 ng /ml. The relations of Vit-D level (taking the median as the cutoff) with clinicopathological factors were assessed using Chi-Square test. Differences in survival outcome were compared using log rank test. Results We screened 340 patients with non-metastatic breast cancer. Baseline Vit-D levels were available for 189 patients. The median age was 50 years (range: 26- 86 years). Noteworthy, 169 (89.4%) of patients had Vit-D level <30 ng/ml with a median of 14.9 ng/ml (range: 4.0 - 45.0). Low Vit-D level (below the median) was significantly more common in premenopausal (p=0.011) and ER-negative patients (p=0.011). However, lymphovascular invasion (p=0.001), clinically (p=0.023) and pathologically positive axillary LNs (p=0.041) were linked with higher Vit- D level. After a median follow up period of 58.2 months, 14 patients died and 40 relapsed. The 5-year disease-free survival (DFS) rates was 74.8%. The 5-year DFS rate in patients with higher Vit-D level above the median was 78.8% compared to 71.1% in patients with lower Vit-D level with no statistically significance difference (p= 0.22). The 5-year overall survival (OS) rate was 90.2%. Meanwhile, no difference in 5-year OS rate in patients with higher and lower Vit-D levels (90.3% and 89.7% respectively, p=0.6). Conclusion Low Vit-D level was prevalent among the studied breast cancer patients. Low Vit-D level was associated with ER-negative phenotype and premenopausal patients. Baseline Vit-D level was not significantly linked with survival outcome.

scholarly journals Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e8298
Author(s):  
Siying Chen ◽  
Jin Yang ◽  
Yang Liu ◽  
Haisheng You ◽  
Yalin Dong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative ◽  
Cox Regression ◽  
Lung Metastases ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Metastatic Sites

Background Reports on the incidence and prognoses of lung metastases when diagnosing breast cancer patients with different subtypes are limited. Our study investigated the effect of molecular sub-typing stratification on the prognoses of lung metastatic breast caner patients. Methods Patients with breast cancer and lung metastases were identified from Surveillance, Epidemiology and End Results population-based data between 2010 and 2015. Univariate and multivariate Cox regression analyses were performed to identify risk factors and prognoses, overall survival (OS) and breast cancer-specific survival for patients with breast cancer lung metastases. Results We identified 6,516 patients with lung metastatic breast cancer, representing 1.7% of the entire cohort and 30.4% of the subset with metastatic disease. This included 2,940 hormone receptor (HR)+/HER2− patients, 852 HR+/HER2+ patients, 547 HR−/HER2+ patients and 983 triple-negative patients. The median OS for all lung metastatic patients was 13 months. Multivariate analysis revealed that those lung metastatic breast cancer patients of older age (>80), black race, with poorly differentiated tumors, carcinoma histology, triple-negative subtype, more metastatic sites and no surgery, and no chemotherapy showed significantly poor survival, both overall and breast cancer-specific. Conclusions Our findings show that molecular sub-type and more metastatic sites might have significant influence on the incidence and prognosis of breast cancer lung metastases. We also identified several prognostic factors that could guide therapy selection in the treatment of lung metastatic patients.

Sign in / Sign up

Export Citation Format

Share Document